Condensed Consolidated Statements of Operations (USD $)	12 Months Ended
	Sep. 30, 2012	Oct. 02, 2011
Income Statement [Abstract]
Product sales	$ 241,600	$ 686,900
Contract research and development revenue	3,954,800	4,491,400
Total revenues	4,196,400	5,178,300
Cost of revenues
Cost of product sales	765,400	234,300
Cost of contract research and development revenue	2,383,600	4,537,400
Total cost of revenues	3,149,000	4,771,700
Gross margin	1,047,400	406,600
General and administrative expense	8,708,800	7,874,600
Research and development expense	7,875,600	3,171,600
Total operating expenses	16,584,400	11,046,200
Loss from operations	(15,537,000)	(10,639,600)
Interest expense	(6,581,100)	(7,544,700)
Change in fair value of derivative Liability	(4,822,100)	1,512,700
Other income (expense)	15,200	(3,400)
Income (loss) from continuing operations before provision for income taxes	(26,925,000)	(16,675,000)
Benefit (provision) for income taxes	(3,200)	37,400
Net loss from continuing operations	(26,928,200)	(16,637,600)
Net earnings from discontinued operations	7,259,800	874,800
Net loss	(19,668,400)	(15,762,800)
Less net loss attributable to noncontrolling interests in subsidiary
Net loss	$ (19,668,400)	$ (15,762,800)
Basic and diluted net loss per common share
Loss from continuing operations	$ (0.22)	$ (0.18)
Net earnings from discontinued operations	$ 0.06	$ 0.01
Net loss per common share	$ (0.16)	$ (0.17)
Basic and diluted weighted average number of common shares outstanding	123,624,400	90,728,100